Home » Markets » House committee questions McKinsey executive over opioid, FDA consulting work
House committee questions McKinsey executive over opioid, FDA consulting work
FOX Business Flash top headlines for April 27
Check out what’s clicking on FoxBusiness.com.
Members of Congress questioned global consulting firm McKinsey & Company's top managing partner Wednesday about the company's work for U.S. health regulators as it advised opioid drugmakers on how to boost painkiller sales.
The House Oversight and Reform Committee asked Bob Sternfels about revelations that the company allowed consultants working for OxyContin maker Purdue Pharma to simultaneously advise the Food and Drug Administration (FDA).
US BARS HAND OUT FREE FENTANYL TESTS: 'IF YOU'RE GOING TO USE DRUGS HERE, YOU CAN TEST THEM'
The hearing is part of an ongoing investigation into McKinsey's role in the opioid crisis.
In 2021, McKinsey agreed to shell out nearly $600 million to settle lawsuits over its work advising opioid makers, though it admitted no wrongdoing.
A preliminary report found that 22 McKinsey consultants worked for both the administration and an opioid manufacturer over the span of a decade.